Why the study?
Surgical or transcatheter aortic valve replacement is currently the only therapy for severe aortic valve stenosis, with no pharmacological treatment available.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Omega-3 polyunsaturated fatty acids and their pro-resolving mediators may offer a novel pharmacological strategy to mitigate inflammation and calcification in aortic valve stenosis.
Inflammation is well-established in cardiovascular disease, including valvular heart disease. Inflammation is a key process in the fibrosis and calcification of the aortic valve leaflets, which ultimately clinically manifest as aortic valve stenosis characterized by valve dysfunction and cardiac obstruction. In the absence of pharmacological treatment, either surgical or transcatheter aortic valve replacement is currently the only available therapeutic strategy for patients with severe aortic valve stenosis. Omega-3 polyunsaturated fatty acids, which exert beneficial effects in several cardiovascular diseases, serve as the substrate for several bioactive lipid mediators that regulate inflammation. Recent findings point to the beneficial effects of omega-3 fatty acids in cardiac valves, being inversely associated with aortic valve calcification and contributing to the resolution of valvular inflammation by means of the pro-resolving mediator resolvin E1 and downstream signaling through its receptor ChemR23.
No takes yet. Share an insight, caveat, or question.
Artiach et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: